For the year ending 2025-12-31, KYTX has $293,826K in assets. $61,550K in debts. $124,093K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 124,093 | |||
| Available-for-sale marketable securities | 155,160 | |||
| Prepaid expenses and other current assets | 3,700 | |||
| Total current assets | 282,953 | |||
| Restricted cash | 551 | |||
| Property and equipment, gross | 5,296 | |||
| Less accumulated depreciation | 3,750 | |||
| Property and equipment, net | 1,546 | |||
| Operating lease right-of-use assets | 3,568 | |||
| Finance lease right-of-use assets | 305 | |||
| Other non-current assets | 4,903 | |||
| Total assets | 293,826 | |||
| Accounts payable | 5,306 | |||
| Accrued compensation | 9,990 | |||
| Accrued license expense - related party | 3,750 | |||
| Other accrued expenses and current liabilities | 13,472 | |||
| Operating lease liabilities, short-term portion | 3,662 | |||
| Finance lease liabilities, short-term portion | 307 | |||
| Total current liabilities | 36,487 | |||
| Operating lease liabilities, net of short-term portion | 320 | |||
| Finance lease liabilities, net of short-term portion | 0 | |||
| Term loan | 24,743 | |||
| Total liabilities | 61,550 | |||
| Common stock, 0.00001 par value 490,000,000 shares authorized as of december 31, 2025 and 2024, respectively 60,389,893 and 43,214,918 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 1 | |||
| Additional paid-in capital | 657,005 | |||
| Accumulated other comprehensive income | 97 | |||
| Accumulated deficit | -424,827 | |||
| Total stockholders' equity | 232,276 | |||
| Total liabilities and stockholders' equity | 293,826 | |||
Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc. (KYTX)